Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director | September 14, 2026 | September 17, 2026 |
| Sight Sciences, Inc.SGHT · Entity 5537 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13 | Direct | 1,187 |
Reported balance
After 2026-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 471 |
Reported balance
After 2026-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Sight Sciences, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,276 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 28,261 · Balance 69,276 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2: Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 37,492 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 37,492 F3: These shares of Common Stock are held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.
F2: Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported.
F3: These shares of Common Stock are held of record by the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is beneficiary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 00:02 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 471 | $0.00 | $0.00 |
DisclosureSEC source: 0001967722-26-000002 · wk-form4_1789603333.xml · derivative · entry 2 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471 Underlying: Common Stock · 471 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 00:02 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $340.03 | $0.00 |
DisclosureSEC source: 0001967722-26-000002 · wk-form4_1789603333.xml · derivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187 Underlying: Common Stock · 1,187 shares Expires 2036-09-13 F1 · derivative.exercise_date: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:09 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 28,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259557 · ownership.xml · nonDerivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,276 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 30,952 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:28 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GiftCommon Stock | 37,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-203807 · ownership.xml · nonDerivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,015 F1 · shares: On September 11, 2025, the Reporting Person transferred the shares to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 (the "Trust"), of which the Reporting Person is a beneficiary, for no consideration. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 21:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $137.46 | $0.00 |
DisclosureSEC source: 0001967722-25-000002 · wk-form4_1751320735.xml · derivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 05, 2025 Filed Jun 11, 2025 01:32 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 30,952 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084609 · ownership.xml · nonDerivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,507 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 37,492 shares of Common Stock, (ii) 30,952 RSUs which are subject to vesting as reported herein, and (iii) 10,063 RSUs granted to the Reporting Person on June 8, 2023 which are subject to vesting as previously reported. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 23:29 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $183.64 | $0.00 |
DisclosureSEC source: 0001967722-24-000003 · wk-form4_1719876543.xml · derivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:35 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 17,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071525 · ownership.xml · nonDerivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,555 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $120,000 divided by the closing price of the Common Stock on the grant date, June 6, 2024. The RSUs vest on the earlier of June 6, 2025 and the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 10,063 shares of Common Stock, (ii) 17,366 RSUs, which are subject to vesting as reported herein, and (iii) 20,126 RSUs granted to the Reporting Person on June 8, 2023, which are subject to vesting as previously reported. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 2,180 | $0.00 Strike: $117.40 | $0.00 |
DisclosureSEC source: 0001711279-23-000059 · wk-form4_1688416510.xml · derivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,180 Underlying: Common Stock · 2,180 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 08, 2023 Filed Jul 3, 2023 22:04 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 30,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016838 · doc4.xml · nonDerivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $240,000 of shares of Common Stock as determined by the closing price on the grant date, June 8, 2023. The RSUs vest in substantially equal installments on each of June 8, 2024, 2025, and 2026, subject to the Reporting Person's continued service as a director on the Company's board of directors through each such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:05 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 13,600 | $0.00 Strike: $80.06 | $0.00 |
DisclosureSEC source: 0001967722-23-000007 · wf-form4_168064231771350.xml · derivative · entry 1 Mazzacco Catherine · CIK 0001967722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2033-03-31 F1 · derivative.exercise_date: The options were awarded on March 31, 2023 and vest in equal monthly tranches over a three-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.